ABSTRACT Peripheral blood leukocytes, obtained from volunteers after vaccination or natural illness with influenza, were assayed for cytotoxicity against influenza virus-infected cells. Approximately 7 days after vaccination or the onset of respiratory illness, peak cytotoxicity was demonstrated in a chromium-release assay. Secretion of specific antibody against hemagglutinin from the leukocytes during in vitro incubation was demonstrated in quantities that would mediate the cell cytotoxicity observed. Antibody secretion was inhibited by exposure to cycloheximide but not by exposure to trypsin. The secretion of antibody against hemagglutinin from peri heral blood leukocytes occurred only at the time of maximal cytotoxicity. We thus demonstrate secretion of specific antibody in vitro after recent viral antigen stimulation. Moreover, this antibody is capable of conveying cytotoxic capacity to peripheral blood leukocytes that may be important in the recovery process from acute viral infection.
secretion of antibody against hemagglutinin from peri heral blood leukocytes occurred only at the time of maximal cytotoxicity. We thus demonstrate secretion of specific antibody in vitro after recent viral antigen stimulation. Moreover, this antibody is capable of conveying cytotoxic capacity to peripheral blood leukocytes that may be important in the recovery process from acute viral infection. Virus-infected cells that express viral antigens on their surface can be lysed by different immunologic components and combinations of components. These include antibody and complement, T cells, antibody plus non-T cells, macrophages, and interferon plus natural killer cells (1) (2) (3) (4) (5) (6) (7) . Studies in animals have demonstrated the importance of T cells in mediating early transient cytotoxicity after viral antigen stimulation (8) (9) (10) . The few human studies that have been performed also demonstrate an early transient rise in cell cytotoxicity to virus-infected cells after antigen stimulation, but these studies have not delineated the effector mechanisms involved (11, 12) .
Previous studies from this laboratory have demonstrated that human peripheral blood leukocytes (PBL) may exhibit cytotoxic activity toward influenza virus-infected cells (13) (14) (15) . In vitro assays using PBL obtained from volunteers at various times after exposure to type A influenza antigens showed a sharp rise in cytotoxic activity on days 3-9 after infection or vaccination and a decline to lower stable levels by day 30 (14, 15) . Cytotoxicity by PBL from volunteers who had a remote experience with influenza antigens was shown to be antibody dependent and mediated by an effector cell with characteristics of "K" cells (14) . The experiments described in the present report are directed toward elucidating the mechanism(s) of the early transient rise in cellular cytotoxicity. The data indicate that PBL at this time are secreting specific antibody against hemagglutinin (AHAb) during a 4-hr period of in vitro incubation in quantities that are sufficient to mediate the cellular cytotoxicity observed.
MATERIALS AND METHODS Subjects. Seven volunteers participated in the studies. Volunteers 1 and 2 were tested sequentially after a natural respiratory illness proven for volunteer 1 to be caused by A/Texas/76 (H3N2) influenza virus (virus isolation and antibody rise) and, with similar testing, proven not to be caused by influenza virus for volunteer 2. Volunteers 2, 3, 4, 5, 6, and 7 were vaccinated with 400 chicken cell agglutinating (CCA) units of an investigational purified subunit vaccine prepared from A/Victoria/75 (H3N2) virus (kindly provided by R. Webster). At the time of vaccination, the six volunteers were healthy and gave no history of recent acute respiratory illness. Vaccination of volunteer 2 was 60 days after his previous noninfluenzal respiratory illness.
Cell Cytotoxicity. The method for cell cytotoxicity has been described (13) (14) (15) . In brief, PBL were obtained from the buffy coat by Ficoll/Isopaque density centrifugation, washed twice in 50 ml of Eagle's minimum essential medium (16) , and added to baby hamster kidney (BHK-21) cells, labeled with 0.1 mCi of 51Cr (Na251CrO4; CJS-1, Amersham/Searle; 1 Ci = 3.7 X 1010 becquerels), that had been inoculated with the A/Port Chalmers recombinant influenza virus (H3pcNeql) or with B/Hong Kong virus. Control target cells consisted of uninfected, chromium-labeled cells. After a 16-to 18-hr incubation, the monolayer cells were trypsinized, washed, and counted by trypan blue exclusion. Five X 104 target cells in 0.1 ml were added to 2.5 X 106 PBL. After a 4-hr incubation at 370C, 3 ml of cold Tris buffer containing 10% fetal calf serum was added, and each tube was centrifuged at 1000 X g for 10 min. The radioactivity in the supernatant fluid and cell sediment from each tube was measured in a gamma counter (Amersham/Searle) to determine the percentage of chromium released from each tube.
The percentage of specific release was calculated from the following formula: 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. centrifuged for 5 min at 800 X g. The eluate was removed and the cells were washed twice in minimal essential medium and recounted. These warmed and washed PBL were used directly in cytotoxicity assays as described above and samples were dispensed into conical centrifuge tubes (5 X 106 cells) with 1 ml of Tris-buffered saline/5% fetal calf serum and incubated at 370C. At 0, 4, or 18 hr after the cells were dispensed, the tubes were centrifuged for 5 min at 800 X g and the supernatant fluid was removed and frozen at -70'C until assayed for antibody or added with heterologous PBL and tested for cytotoxicity. Trypan blue exclusion was performed on the cell pellet in each test.
In three vaccinated volunteers, PBL (5 X 106 cells) obtained on day 7 were treated with 2.5 ,ug of purified trypsin per ml (TPCK-treated, Worthington) for 30 min at 370C and then washed twice with minimum essential medium/5% fetal calf serum. AT 0, 1, 4, and 18 hr after trypsin treatment, the tubes were centrifuged for 5 min at 800 X g and the supernatant fluid was removed and frozen at -70'C until assayed for antibody or added with heterologous PBL and tested for cytotoxicity. Similar studies were performed with day 7 PBL that had been incubated with 0.5-1 ,tg of cycloheximide per ml (Sigma) for 45 min at 370C and then washed and reincubated with cycloheximide for the various incubation time periods.
Supernatants obtained from the PBL of volunteers 1-5 were added to warmed and washed PBL that had been obtained from an individual who had had no recent exposure to influenza virus antigen. These heterologous PBL gave low or no specific release. The percent specific release is derived from the percent release in the presence of prewarmed heterologous PBL and supernatant fluids less the percent release in the presence of PBL alone.
Adsorption of Supernatants. Eighteen-hour supernatants were adsorbed for 18 hr at 4°C with goat anti-human IgG 1:12 (Qy chain specific). To facilitate precipitation, antibody-free carrier serum was added in equivalence with goat antiserum before adsorption.
Antibody Assays. AHAb binding capacity in both plasma and supernatant fluids was determined by radioimmunoprecipitation assays described earlier, except that data are here expressed as binding capacity rather than titer (17) . All samples were tested with iodinated preparations of both A/Port Chalmers/73 and A/Victoria/75 hemagglutinin antigens. As an equally sensitive control test with a different antigen, samples were tested for antibody to the hexon subunit of adenovirus type 5 in a similar radioimmunoprecipitation assay (18) .
Interferon Assay. A yield reduction assay using vesicular stomatitis virus as the challenge virus was used to measure inteferon activity in supernatant fluids (19) .
RESULTS
Cell Cytoxicity during Natural Infection with Influenza. Volunteer 1 was tested for cell cytotoxicity after the onset of an acute respiratory illness caused by type A influenza virus (Fig.  1A) . PBL and PBL that had been additionally warmed and washed had elevated levels of percent specific release (48.3 and 43.5%, respectively) to H3pcNeql (PC)-infected cells approximately 7 days after the onset of symptoms. By day 35, the percent specific release for each PBL fraction had dropped significantly (2.2 and 0%, respectively). Approximately 60 days after the onset of his illness, the value in the PBL fraction after warming and washing was 0%, although 24% was detected before the cells were warmed and washed.
Radioimmunoprecipitation assays of supernatant fluids obtained from warmed PBL before and after 4 and 18 hr of incubation revealed an increase in antigen-binding capacity for Port Chalmers hemagglutinin between the 0-hr and 4-hr supernatant samples only on days 7 and 17 after onset of illness (0.80 and 0.10 ng/50 Al, respectively). The 18-hr sample on day 7, but not on day 17 , had an increase in antigen-binding capacity over the 0-hr sample that was greater than that measured for the 4-hr sample. No antibody activity was detected in the 0-, 4-, or 18-hr samples obtained on the other days tested (day 4, 35, or 60). All supernatants were tested and were negative for antibody to adenovirus type 5 hexon. The 4-hr and 18-hr supernatant samples obtained on day 7 were tested for interferon and all were negative (<1 unit/ml).
In order to evaluate the cytotoxic potential of in nitro released AHAb, we added the 4-hr supernatants obtained on each day with heterologous PBL that had been warmed and washed to H3pcNeql-and B/Hong Kong-infected target cells. Only those supernatants obtained on days 7 and 17 conferred cytotoxic capacity to the heterologous PBL when they were added to the H3pcNeql target cells. No increases in cytotoxicity were demonstrated for any 4-hr supernatants added with heterologous PBL to the B/Hong Kong-infected cells.
Volunteer 2 was tested for cell cytotoxicity and specific influenza AHAb production after an acute respiratory illness that was not caused by type A influenza virus (Fig. 1B) . No significant changes in cell cytotoxicity were found in the days tested. In addition, supernatants obtained from the PBL that were warmed, washed, and subsequently incubated failed to dem- 
cells <40%).
No increases in cytotoxicity were seen for the 4-hr supernatants obtained on other days when compared with the cytotoxicity of the PBL alone, and no increase in cytotoxicity was seen for any of the 4-hr supernatants added with heteroiogous PBL to B/Hong Kong-infected target cells.
Effect of Trypsin and Cycloheximide on Release of AHAb from PBL. Volunteers 5, 6, and 7 were vaccinated with the same inactivated vaccine and their PBL were removed and tested for release of AHAb on day 7. An aliquot of PBL was incubated in minimum essential medium/5% fetal calf serum after they had been warmed and washed, and supernatants were removed 0, 1, 4, and 18 hr later and assayed for antigenbinding capacity by radioimmunoprecipitation. A second aliquot of PBL was incubated with trypsin or cycloheximide, and supernatants were removed as before and tested in a similar manner. Trypsin treatment did not alter the production of AHAb compared with the PBL incubated only with medium (Table 3) . However, cycloheximide significantly inhibited the AHAb released from PBL. Viability of PBL ranged from 65 to 90% at 18 hr.
Sufficient supernatant fluids were available from volunteer 5 for testing in a cytotoxicity assay. Supernatant fluids from the warmed and washed and the trypsin-treated PBL, but not the cycloheximide-treated PBL, conferred cytotoxicity when added to heterologous PBL. Effect of Supernatant Adsorption with Goat Anti-Human IgG. Eighteen-hour supernatants obtained on day 7 after illness in volunteer 1 or on day 7 after vaccination in volunteers 2 and 3 were tested for the ability to confer cytotoxic capacity after adsorption with goat anti-human IgG. The adsorbed supernatant samples had no detectable AHAb activity as measured by radioimmunoprecipitation and failed to confer cytotoxic capacity to H3pcNeql-infected cells when added with heterologous PBL that had been warmed and washed. DISCUSSION These experiments indicate that PBL obtained after natural illness or vaccination with type A influenza viruses are actively secreting AHAb 7 days after antigen stimulation. The AHAb that is secreted from PBL during a 4-hr incubation is capable of conferring cytotoxic capacity to heterologous PBL when added to target cells infected with influenza A but not those infected with influenza B virus. Trypsin treatment of PBL did not alter the secretion of AHAb whereas cycloheximide, an inhibitor of protein synthesis, significantly reduced the measurable AHAb during an 18-hr incubation. The failure of trypsin to inhibit the reaction suggests that the antibody is not cytophilic. The failure to detect interferon secretion demonstrates that one is not observing interferon-mediated natural killer cell reaction (6) . Therefore, the early transient rises in cell cytotoxicity by PBL that persisted after incubation for 30 min at 370C and repeat washing in our earlier studies was probably due to the AHAb secreted in the 4-hr interval used for the chromium release assay.
The demonstration in humans of secretion of specific antibody in vitro after recent in vivo viral antigen stimulation has not been reported previously. Similar results in mice with nonviral antigens have been reported and are consistent with our results. Schirrmacher et al. (20) demonstrated that antigen-coated chicken erythrocytes were lysed in the presence of nonimmune spleen cells and an active factor that was released from immune spleen cells. The immunoglobulin nature of this factor was indicated by its precipitability in half-saturated ammonium sulfate and its removal by matrix-bound anti-mouse gamma globulin. Recent studies have confirmed these findings, with sheep erythrocytes as the immunizing antigen (21) .
The extent of influenza A antibody synthesis by PBL remains to be determined. Because these volunteers had been previously exposed to influenza A virus, synthesis of AHAb to other H3 variants, or to earlier subtypes, may also have occurred. AHAb to both A/Port Chalmers and A/Victoria hemagglutinin was detected in the supernatants on day 7 after vaccination, but only by radioimmunoprecipitation. Other standard tests for influenza antibody (i.e., neutralization or hemagglutination inhibition) would not have detected the low levels of antibody in these supernatant fluids.
There was an apparent lack of correlation between the percent specific release measured in PBL, the antibody levels detected in the supernatants, and the percent specific release measured when the supernatants were added to heterologous PBL. The 4-hr supernatants obtained on day 7 (14) . However, B cells (22, 23) , K cells (24) , macrophages (25) , and even T cells (26, 27) have also been implicated as effector cells in antibody-dependent cell cytotoxicity. K 
